Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with high tumor mutational burden tumors.
Advanced solid tumor
Clinical practice guideline
Immunotherapy
PD-1/PD-L1 inhibitor
Tumor mutation burden-high (TMB-H)
Journal
International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
13
03
2023
accepted:
18
05
2023
medline:
1
8
2023
pubmed:
10
6
2023
entrez:
10
6
2023
Statut:
ppublish
Résumé
The development of novel antitumor agents and accompanying biomarkers has improved survival across several tumor types. Previously, we developed recommendations for tumor-agnostic treatments in patients with solid tumors with DNA mismatch repair deficient or neurotrophic receptor tyrosine kinase fusions. Recently, immune checkpoint inhibitors have shown efficacy in patient with tumor mutation burden-high (TMB-H) solid tumors and have been established as a third tumor-agnostic agent, making it necessary to develop the guideline prioritized for these patients. Clinical questions regarding medical care were formulated for patients with TMB-H advanced solid tumors. Relevant publications were searched by PubMed and Cochrane Database. Critical publications and conference reports were added manually. Systematic reviews were performed for each clinical question for the purpose of developing clinical recommendations. The committee members identified by Japan Society of Clinical Oncology (JSCO), Japanese Society of Medical Oncology (JSMO), and Japanese society of pediatric hematology/oncology (JSPHO) voted to determine the level of each recommendation considering the strength of evidence, expected risks and benefits to patients, and other related factors. Thereafter, a peer review by experts nominated from JSCO, JSMO, and JSPHO, and the public comments among all societies' members was done. The current guideline describes three clinical questions and seven recommendations for whom, when, and how TMB should be tested, and what is recommended for patients with TMB-H advanced solid tumors. In this guideline, the committee proposed seven recommendations for performing TMB testing properly to select patients who are likely to benefit from immunotherapy.
Identifiants
pubmed: 37300720
doi: 10.1007/s10147-023-02360-8
pii: 10.1007/s10147-023-02360-8
pmc: PMC10390617
doi:
Substances chimiques
B7-H1 Antigen
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Practice Guideline
Langues
eng
Sous-ensembles de citation
IM
Pagination
941-955Informations de copyright
© 2023. The Author(s).
Références
Nature. 2013 Jul 11;499(7457):214-218
pubmed: 23770567
Cancer Sci. 2019 Apr;110(4):1480-1490
pubmed: 30742731
J Clin Oncol. 2019 Feb 1;37(4):318-327
pubmed: 30557521
Ann Oncol. 2021 May;32(5):661-672
pubmed: 33736924
Nat Med. 2017 Jun;23(6):703-713
pubmed: 28481359
Nat Med. 2019 Sep;25(9):1415-1421
pubmed: 31501609
J Clin Oncol. 2022 Apr 10;40(11):1231-1258
pubmed: 35175857
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32217756
Am Soc Clin Oncol Educ Book. 2018 May 23;38:998-1007
pubmed: 30231318
Int J Clin Oncol. 2020 Mar;25(3):403-417
pubmed: 31974683
Science. 2015 Apr 3;348(6230):69-74
pubmed: 25838375
N Engl J Med. 2021 Apr 1;384(13):1191-1203
pubmed: 33789008
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Nat Rev Drug Discov. 2020 Jun;19(6):383-384
pubmed: 32494047
Nat Genet. 2019 Feb;51(2):202-206
pubmed: 30643254
Clin Cancer Res. 2017 Oct 1;23(19):5729-5736
pubmed: 28972084
Nature. 2012 Feb 08;482(7385):400-4
pubmed: 22318521
Br J Cancer. 1955 Dec;9(4):652-7
pubmed: 13304228
JAMA Oncol. 2021 May 01;7(5):739-743
pubmed: 33599686
Ann Oncol. 2018 May 1;29(5):1211-1219
pubmed: 29438522
Lancet Oncol. 2020 Oct;21(10):1353-1365
pubmed: 32919526
Int J Clin Oncol. 2020 Feb;25(2):217-239
pubmed: 31286289
Breast Cancer Res Treat. 2014 Jul;146(1):211-20
pubmed: 24839032
Cell. 2015 Jan 15;160(1-2):48-61
pubmed: 25594174
Clin Cancer Res. 2015 Aug 15;21(16):3631-9
pubmed: 25567908
Genome Med. 2017 Apr 19;9(1):34
pubmed: 28420421
N Engl J Med. 2018 May 10;378(19):1789-1801
pubmed: 29658430
Nat Med. 2018 Sep;24(9):1441-1448
pubmed: 30082870
N Engl J Med. 2018 Dec 13;379(24):2342-2350
pubmed: 30280658
N Engl J Med. 2017 Dec 21;377(25):2500-2501
pubmed: 29262275
J Clin Oncol. 2010 Jun 20;28(18):3042-7
pubmed: 20479405
Ann Oncol. 2019 Jan 1;30(1):44-56
pubmed: 30395155
Nature. 2020 Apr;580(7804):517-523
pubmed: 32322066
BMC Med. 2016 Oct 25;14(1):168
pubmed: 27776519
Cancer Res. 2012 Mar 1;72(5):1081-91
pubmed: 22237626
Genome Med. 2016 Jul 26;8(1):79
pubmed: 27460824
Ann Oncol. 2020 Jul;31(7):861-872
pubmed: 32272210
J Clin Oncol. 2021 Aug 1;39(22):2443-2451
pubmed: 33844595